9% of pediatric tuberculosis patients found resistant to drug, says a new survey
Advertisement
India as a country continues to suffer from a staggering figure in TB cases, with two deaths reported every three minutes, and most recently bearing the highest number of such cases in the world.
In a new study by the Revised National TB Control Programme (RNTCP), more alarming fact has been thrown at us; considering now that almost 9% of all pediatric tuberculosis patients are resistant to rifampicin. (as confirmed by a report in the Times of India).
The project details further confirmed that 8% of the 22,000 suspected pediatric TB cases (0-14 years) not only just tested positive, but were also found resistant to one of the finest drug to treat the disease. This is 6% more than what was previously estimated, a study covering four metros, including Chennai, Hyderabad, Kolkata and Delhi.
Further considering the break-up in these 4 metros, Delhi has the highest percentage of TB suffering children (12.2%) followed by Chennai which has the least number of reported cases. Kolkata has the highest TB resistance rate at 12%.
In a new study by the Revised National TB Control Programme (RNTCP), more alarming fact has been thrown at us; considering now that almost 9% of all pediatric tuberculosis patients are resistant to rifampicin. (as confirmed by a report in the Times of India).
The project details further confirmed that 8% of the 22,000 suspected pediatric TB cases (0-14 years) not only just tested positive, but were also found resistant to one of the finest drug to treat the disease. This is 6% more than what was previously estimated, a study covering four metros, including Chennai, Hyderabad, Kolkata and Delhi.
Further considering the break-up in these 4 metros, Delhi has the highest percentage of TB suffering children (12.2%) followed by Chennai which has the least number of reported cases. Kolkata has the highest TB resistance rate at 12%.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.